International comparison of treatment strategy and survival in metastatic gastric cancer
Autor: | Lone Susanne Jensen, Jakob Hedberg, Marije Slingerland, Rob H.A. Verhoeven, Egil Johnson, Geir Olav Hjortland, Esther Bastiaannet, T. Koessler, J. L. Dikken, E. Van Eycken, William H. Allum, Mats Lindblad, C.J.H. van de Velde, Mickael Chevallay, H. J. Larsson, W.O. de Steur, Henk H. Hartgrink, H. De Schutter, Yvette Claassen |
---|---|
Rok vydání: | 2018 |
Předmět: |
Chemotherapy
education.field_of_study medicine.medical_specialty Relative survival business.industry medicine.medical_treatment Population Cancer General Medicine medicine.disease Chemotherapy regimen 03 medical and health sciences 0302 clinical medicine 030220 oncology & carcinogenesis Internal medicine medicine 030211 gastroenterology & hepatology Gastrectomy business education Survival rate Survival analysis |
Zdroj: | BJS Open. 3:56-61 |
ISSN: | 2474-9842 |
Popis: | Background In the randomized Asian REGATTA trial, no survival benefit was shown for additional gastrectomy over chemotherapy alone in patients with advanced gastric cancer with a single incurable factor, thereby discouraging surgery for these patients. The purpose of this study was to evaluate treatment strategies for patients with metastatic gastric cancer in daily practice in five European countries, along with relative survival in each country. Methods Nationwide population-based data from Belgium, Denmark, the Netherlands, Norway and Sweden were combined. Patients with primary metastatic gastric cancer diagnosed between 2006 and 2014 were included. The proportion of gastric resections performed and the administration of chemotherapy (irrespective of surgery) within each country were determined. Relative survival according to country was calculated. Results Overall, 15 057 patients with gastric cancer were included. The proportion of gastric resections varied from 8·1 per cent in the Netherlands and Denmark to 18·3 per cent in Belgium. Administration of chemotherapy was 39·2 per cent in the Netherlands, compared with 63·2 per cent in Belgium. The 6-month relative survival rate was between 39·0 (95 per cent c.i. 37·8 to 40·2) per cent in the Netherlands and 54·1 (52·1 to 56·9) per cent in Belgium. Conclusion There is variation in the use of gastrectomy and chemotherapy in patients with metastatic gastric cancer, and subsequent differences in survival. |
Databáze: | OpenAIRE |
Externí odkaz: |